Omega CRO is a Contract Research Organization that provides high quality clinical and epidemiological research management to national and international pharmaceutical companies and other health-related organizations.
Omega CRO, founded in March 1997, is the first CRO in Turkey. With its full range of services, Omega CRO is an independent research organization specialized in Phase III and IV clinical trials and post marketing surveys.
Omega senior staff has much experience on not only planning, conducting and monitoring clinical and epidemiological studies, but also data management, data analysis, presentation of data and bioinformatics. With extensive experience in clinical research from both industry and investigator perspectives, they had managed clinical trials in many major therapeutic areas. Other areas of experience include large-scale surveys and outcomes research. Omega also offers training programs for pharmaceutical companies and investigators. In addition, Omega develops and publishes educational materials as well as periodicals and serials.
Contact Details
Ankara Office: Güniz Sok. 32/12
06700 K.dere, Ankara
Phone:+90 312 426 77 22
Fax: +90 312 427 74 56
Istanbul Office: Agaoglu Eltes Gold Residence Madenler Mah. Sehit Unal Kalafat Cad.No:32 Kat: 23 Dai:251 Yukarı Dudullu Umraniye İstanbul
Phone:+90 216 339 00 55
Fax:+90 216 339 00 56
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million…
Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also…
Sevi Firat, Founding Partner of Firat Izgi discusses the legal challenges facing pharmaceutical companies looking to penetrate the healthcare market in Turkey, the evolution of the legal landscape and her…
Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over…
A founding partner of YükselKarkınKüçük, Gökhan Gökçe discusses the firm’s involvement with several high profile cases concerning the healthcare and life science sector’s reference pricing system, and also elaborates on…
The managing director of DHL Express Turkey, Markus Reckling highlights the strategic importance of Turkey to the global DHL Express portfolio and elaborates on the market opportunities present for DHL’s…
The co-founder of Ekin Kimya discusses the need for greater regulation and monitoring of raw materials used in Turkish pharmaceutical manufacturing, his company’s key role as an educator and advisor…
Novartis country president Peter Catalino discusses the need for Turkey to introduce financial investment incentives to compete more effectively with other countries for investments in R&D and manufacturing. You arrived…
The chairman and CEO of Santa Farma discusses how the Turkish pharmaceutical landscape has evolved in response to the government’s healthcare transformation programs. He also enumerates various strategic initiatives the…
Omega CRO has evolved from its beginnings as a CRO contracted by local and multinational pharmaceutical companies into an organization leading clinical, epidemiological and observational studies of public interest across…
The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming a PIC/s member, and…
The CEO of Centurion shares his ambitious vision for the company’s expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing sales in more than…
See our Cookie Privacy Policy Here
